FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308395736> ?p ?o ?g. }

• W4308395736 abstract "<h3>Background</h3> Defining the optimal dosing-schedule is critical for the development of novel immunotherapeutic combinations. We recently completed phase 1/2 testing of ONCOS-102, a GM-CSF-encoding oncolytic adenovirus (Ad5/3-D24-GMCSF) in two different dosing schedules in combination with pembrolizumab (pem) in patients (pts) with unresectable, stage III-IV, anti-PD-1 resistant/refractory melanoma (NCT03003676). Here, we report tumor viral exposure, comparative, longitudinal gene expression analysis of tumor samples, safety, and detailed analysis of local and systemic effects on tumor lesions according to dosing schedule. <h3>Methods</h3> In study Part 1, pts (n=9) received sequential treatment comprising three priming injections of ONCOS-102 (3x1011 VP/injection, intra-tumoral) at every 3 days during the first week of treatment followed by i.v. pem administration (10 mg/kg) every 3 weeks from day 22 for 6 months. In study part 2, pts (n=12) received concomitant treatment with three priming injections of ONCOS-102 during the first week and at day 15 and then ONCOS-102+pem every 3 weeks from day 22. Injected and non-injected target lesion response was assessed, and tumor biopsies were collected at baseline, day 22 and 64. Total RNA sequencing with differential gene expression analysis was conducted on samples from 17 pts. AEs were assessed according to CTCAE. <h3>Results</h3> 35% (7 of 20) of evaluable patients achieved RECIST v1.1 objective response. ORR was similar in the two cohorts: 38% (3 of 8 patients) in Part 1 and 33% (4 of 12 patients) in Part 2, despite evidence of more advanced disease in Part 2. Fifty-two individual target lesions (TL) were assessed for response; 16 injected (I)-TL and 36 non-injected (NI)-TL. In I-TL, 25% completely regressed. In NI-TL, ≥ 30% shrinkage was observed in 1 of 8 (12.5%) in Part 1 vs 7 of 28 (25%) in Part 2. Greater persistence of ONCOS-102 DNA in the tumor through day 64 was observed in Part 2. This correlated with an increased expression of immune-related genes particularly at day 64. The most frequently reported TEAEs were pyrexia (48%), chills (43%), hypertension (43%), nausea (33%), and alanine aminotransferase increase (33%) with similar incidence, and severity in both parts. <h3>Conclusions</h3> Repeat dosing concomitantly with pembrolizumab demonstrated greater viral persistence in the tumor and a trend for upregulation of immune-related genes at Day 64, with no added toxicity concerns beyond pyrexia and local injection site events. Persisting immune activation and substantial tumor shrinkage in non-injected lesions supports the extended (Part 2) dosing regimen for further clinical development. <h3>Trial Registration</h3> NCT03003676 <h3>Ethics Approval</h3> The study obtained ethics approval in the US by: 1. Memorial Sloan Kettering Cancer Center Institutional Review Board/Privacy Board 1275 York-Avenue, New York 10065 Name of committee chair:R. Michael Tuttle, MD. Protocol # 16-1107 2. Fox Chase Cancer Center WCG IRB 101939 Ave SE/Suite 120, Puyallup, WA 98374 Name of committee chair: Dawn Flitcraft FCCC Study # 17-1083 3. University of Maryland Institutional Review Board 22 S. Greene Street, Baltimore, Maryland 21201 Name of committee chair: Mark Mishra, MD HP-00078557/17121GCCC and in Norway by 4. REK sør-øst A Gullhaugveien 1-3, 0484 Oslo Name of committee chair.: Knut Engedal All participants gave informed consent before taking part." @default.
• W4308395736 created "2022-11-11" @default.
• W4308395736 creator A5000804958 @default.
• W4308395736 creator A5008658583 @default.
• W4308395736 creator A5027374550 @default.
• W4308395736 creator A5040291209 @default.
• W4308395736 creator A5054656505 @default.
• W4308395736 creator A5076736008 @default.
• W4308395736 creator A5080084632 @default.
• W4308395736 creator A5080899662 @default.
• W4308395736 date "2022-11-01" @default.
• W4308395736 modified "2023-09-23" @default.
• W4308395736 title "615 Repeat dosing of oncolytic adenovirus ONCOS-102 is associated with enhanced and persistent immune responses and improved systemic activity in anti-PD-1 resistant/refractory (r/r) melanoma" @default.
• W4308395736 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0615" @default.
• W4308395736 hasPublicationYear "2022" @default.
• W4308395736 type Work @default.
• W4308395736 citedByCount "1" @default.
• W4308395736 countsByYear W43083957362023 @default.
• W4308395736 crossrefType "proceedings-article" @default.
• W4308395736 hasAuthorship W4308395736A5000804958 @default.
• W4308395736 hasAuthorship W4308395736A5008658583 @default.
• W4308395736 hasAuthorship W4308395736A5027374550 @default.
• W4308395736 hasAuthorship W4308395736A5040291209 @default.
• W4308395736 hasAuthorship W4308395736A5054656505 @default.
• W4308395736 hasAuthorship W4308395736A5076736008 @default.
• W4308395736 hasAuthorship W4308395736A5080084632 @default.
• W4308395736 hasAuthorship W4308395736A5080899662 @default.
• W4308395736 hasBestOaLocation W43083957361 @default.
• W4308395736 hasConcept C121608353 @default.
• W4308395736 hasConcept C126322002 @default.
• W4308395736 hasConcept C142424586 @default.
• W4308395736 hasConcept C143998085 @default.
• W4308395736 hasConcept C2777288759 @default.
• W4308395736 hasConcept C2777658100 @default.
• W4308395736 hasConcept C2779384505 @default.
• W4308395736 hasConcept C502942594 @default.
• W4308395736 hasConcept C71924100 @default.
• W4308395736 hasConcept C82210918 @default.
• W4308395736 hasConcept C86803240 @default.
• W4308395736 hasConcept C87355193 @default.
• W4308395736 hasConcept C90924648 @default.
• W4308395736 hasConceptScore W4308395736C121608353 @default.
• W4308395736 hasConceptScore W4308395736C126322002 @default.
• W4308395736 hasConceptScore W4308395736C142424586 @default.
• W4308395736 hasConceptScore W4308395736C143998085 @default.
• W4308395736 hasConceptScore W4308395736C2777288759 @default.
• W4308395736 hasConceptScore W4308395736C2777658100 @default.
• W4308395736 hasConceptScore W4308395736C2779384505 @default.
• W4308395736 hasConceptScore W4308395736C502942594 @default.
• W4308395736 hasConceptScore W4308395736C71924100 @default.
• W4308395736 hasConceptScore W4308395736C82210918 @default.
• W4308395736 hasConceptScore W4308395736C86803240 @default.
• W4308395736 hasConceptScore W4308395736C87355193 @default.
• W4308395736 hasConceptScore W4308395736C90924648 @default.
• W4308395736 hasLocation W43083957361 @default.
• W4308395736 hasOpenAccess W4308395736 @default.
• W4308395736 hasPrimaryLocation W43083957361 @default.
• W4308395736 hasRelatedWork W1984309643 @default.
• W4308395736 hasRelatedWork W2106653639 @default.
• W4308395736 hasRelatedWork W2351796763 @default.
• W4308395736 hasRelatedWork W2918185451 @default.
• W4308395736 hasRelatedWork W2981372661 @default.
• W4308395736 hasRelatedWork W3208389371 @default.
• W4308395736 hasRelatedWork W4221070417 @default.
• W4308395736 hasRelatedWork W4248512896 @default.
• W4308395736 hasRelatedWork W4322724425 @default.
• W4308395736 hasRelatedWork W1752145295 @default.
• W4308395736 isParatext "false" @default.
• W4308395736 isRetracted "false" @default.
• W4308395736 workType "article" @default.